AstraZeneca PLC (AZN) Meet the Management at ESMO 2024 Conference (Transcript)
https://seekingalpha.com/article/4721728-astrazeneca-plc-azn-meet-management-esmo-2024-conference-transcript?source=feed_sector_transcripts
Sep 17, 2024 - AstraZeneca PLC (NASDAQ:AZN) Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief Executive...
0
Relay Stock Soars on Upbeat Data From Breast Cancer Study
https://www.zacks.com/stock/news/2334138/relay-stock-soars-on-upbeat-data-from-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334138
Sep 10, 2024 - RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
0
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
https://www.zacks.com/stock/news/2329912/merck-scraps-two-late-stage-keytruda-studies-on-disappointing-data?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2329912
Aug 30, 2024 - MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.
0
Top Analyst Reports for Linde, AstraZeneca & Walt Disney
https://www.zacks.com/commentary/2328320/top-analyst-reports-for-linde-astrazeneca-walt-disney?cid=CS-ZC-FT-research_daily-2328320
Aug 28, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AstraZeneca PLC (AZN) and The Walt Disney Company (DIS), as well as two micro-cap stocks FitLife Brands, Inc. (FTLF) and Utah Medical Products, Inc. (UTMD).
0
J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC
https://www.zacks.com/stock/news/2328493/j-j-s-rybrevant-receives-eu-approval-for-expanded-use-in-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2328493
Aug 28, 2024 - The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.
0
Roche Obtains Approval For its Rare Blood Disorder Drug in the EU
https://www.zacks.com/stock/news/2327876/roche-obtains-approval-for-its-rare-blood-disorder-drug-in-the-eu?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2327876
Aug 27, 2024 - RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.
0
Insmed Stock Surges 168% in the Past Six Months: Here's Why
https://www.zacks.com/stock/news/2327841/insmed-stock-surges-168-in-the-past-six-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2327841
Aug 27, 2024 - Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.
0
Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review
https://www.zacks.com/stock/news/2325849/bristol-myers-bmy-hcc-combo-drug-accepted-for-fda-review?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2325849
Aug 22, 2024 - Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.
0
J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy
https://www.zacks.com/stock/news/2325154/j-j-jnj-gets-fda-nod-for-chemotherapy-free-lung-cancer-therapy?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2325154
Aug 21, 2024 - The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.
0
How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?
https://www.zacks.com/stock/news/2316191/how-should-you-play-astrazeneca-azn-after-q2-beat-view-raise?cid=CS-ZC-FT-analyst_blog|rank_focused-2316191
Aug 16, 2024 - AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.
0
Page 1>